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Abstract 
Review on deletion of 6q in hematological 
malignancies, genes involved and clinical 
significances 
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Identity 
Note 
Deletions of 6q are characteristic of lymphoid 
malignancies, but rare in myeloid diseases. In solid 
tumor 6q deletions have been reported in melanoma, 
renal cell carcinoma, salivary gland 
adenocarcinoma, ovarian carcinoma and breast 
cancer highlighting the importance of this region in 
cancer development. 
Clinics and pathology 
Disease 
Various hematological malignancies: B- and T- 
lineages acute lymphoblastic leukemia (ALL),  
chronic lymphocytic leukemia (CLL), Non-Hodgkin 
lymphoma (NHL), Hodgkin lymphoma (HL), 
plasma cell myeloma (PCM), Waldenström 
macroglobulinemia (WM), natural killer cell 
leukemia/lymphoma (NK), myelodysplastic 
syndrome (MDS), acute myeloid leukemia (AML). 
Epidemiology 
Deletions affecting chromosome 6q are among the 
most commonly observed structural aberrations in 
lymphoid malignancies (Taborelli et al, 2006). 
Deletions can include the whole long arm or specific 
regions of 6q. The frequency of 6q deletions varies 
depending on disease histology and methodology 
used; the deletions have been identified by karyotype 
in 4% - 13% of ALL and in 13% - 33% of various 
subtypes of lymphoma. However, molecular studies 
of loss of heterozygosity (LOH) and fluorescence in 
situ hybridization (FISH) have detected a higher 
frequency of 6q deletions in up to 50% of lymphoma 
cases and in 30% of ALL cases. 
Cytogenetics 
In the majority of cases, loss of 6q results from an 
interstitial deletion.  Other structural abnormalities 
leading to 6q deletions such as isochromosome 6p, 
add(6q) or der(6) are less frequent (Figure 1). The 6q 
deletion is usually associated with other karyotypic 
abnormalities; it is infrequently reported as the sole 
abnormality suggesting that 6q deletion is a 
secondary change play a relevant role in the 
progression of the disease.  
The deletions of 6q are variable in size and have 
heterogeneous breakpoints. Based on chromosome 
analysis, Offit et al identified three regions of 
minimal cytogenetic deletions in a series of 94 NHL 
patients with deleted 6q; these regions were 6q21, 
6q23, and 6q25-27 (Offit et al 1993).  
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Figure 1.  Partial G-banded karyotypes showing various size of 6q deletions in lymphoid malignancies. 
 
Further investigations, Zhang et al attempted to 
delineate deletions of 6q in a large series of B- and 
T-cell NHLs and acute leukemia using a panel of 36 
YAC FISH probes distributed from 6q12 to 6q27 and 
a centromeric probe of chromosome 6 as internal 
control. They identified a commonly deleted region 
of 3 cM (4-5 Mb) in the 6q21 suggesting that this 
region harbors a putative tumor suppressor gene(s) 
involved in the pathogenesis of both low-grade and 
high-grade NHL as well as ALL (Zhang et al 2000). 
Disease 
Acute Lymphoblastic Leukemia (ALL) 
Note 
Based on banded chromosome, deletions of 
chromosome 6q occur in 4-13% of B-lineage ALL 
and in 20-30% of T-lineage ALL. Molecular studies 
of LOH in ALL have shown higher incidences of 6q 
deletions in 7-32% of cases with most of the 
deletions are being interstitial. In a large study 
conducted by Children Cytogenetic Group (CCG), 
Heerema et al reported deletions of 6q in 9% of a 
newly diagnosed pediatric ALL; 20% of those 
patients had  6q deletion as a sole abnormality and in 
other 13% the deletion was seen in a sideline as a 
secondary abnormality. Hayashi et al observed a 
common region of deletion at 6q21 in 45 children 
with ALL, and Takeuchi et al described two regions 
of deletion both involving 6q21 among 19 pediatric 
ALL cases with deleted 6q (Hayashi et al 
1990;Takeuchi et al 1998). In contrast the deleted 
region appears to be more proximal in T-ALL at 
6q16. Deletions of 6q occur most often with other 
recurring aberrations including 9p, 12p, 13q, 14q or 
11q23 and/or trisomy of chromosome I6 or 21 but 
are less likely to be associated with a hyperdiploid 
karyotype (Heerema et al 2000). The use of FISH 
panel for clinical diagnosis reveals a strong 
association of 6q deletions with 12p ETV6/ RUNX1 
positive ALL. 
Clinics 
ALL patients with deletions 6q are more likely to 
have high WBC counts at presentation, mediastinal 
mass, CNS involvement, T-lineage 
immunophenotype, and/or pseudodiploid karyotype. 
Prognosis 
The clinical data from large studies demonstrated 
that the outcome for patients with or without 6q 
deletion is similar regardless of NCI risk 
classification or immunophenotype. Thus, deletion 
of 6q is not associated with an adverse risk in ALL 
(Hayashi 1990, Heerema et al 2000). 
Disease 
Chronic Lymphocytic Leukemia (CLL) 
Note 
6q deletions are found in 3-6% of evaluable CLL 
cases by banded chromosomes.  However, FISH on 
interphase cells has improved the sensitivity for 
detection of genetic abnormalities in B-CLL.  In a 
large series of 285 CLL patients, two YAC FISH 
probes mapping to 6q21 and 6q27 regions were used. 
The deletions of 6q were identified in 7% of patients; 
the 6q21 region was deleted in all cases whereas the 
6q27 region was deleted only in a third of those cases 
(Stilgenbauer S et al, 1999). Furthermore, this study 
found that patients with 6q deletions had higher 
white blood cell counts and more extensive 
lymphadenopathy but no inferior outcome. In 
another large study by Cuneo et al, chromosome and 
FISH analyses were performed on 217 CLL patients. 
The deletion of 6q21 was identified in 20 patients 
(7.2%) 13 of those (4.7%) had an isolated 6q21 
deletion (Cuneo et al 2004). Recent study by Dalsass 
et al using a panel of four probes mapped to 6q16, 
6q23, 6q25, 6q27 was performed on 107 CLL cases 
to evaluate the incidence and localization of the 
deleted region(s) at 6q.  
They found 6q deletions in 11 cases (10.5%), a 
higher frequency than the previous reports; in five of 
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those cases (4.7%) 6q deletion was a sole 
abnormality. The additional abnormalities in the 
other six cases were trisomy 12, 13q- , 14q-, or 
complex karyotype. The most frequently deleted 
region in their study was in 6q16 (63.6%) followed 
by 6q25.2 (36.4%) region (Dalsass et al 2013). 
Clinics 
CLL patients with an isolated 6q21 deletion may 
represent a cytogenetic and clinicobiological entity 
characterized by relatively high WBC, high 
incidence of atypical morphology, classical 
immunophenotype with CD38 positivity, 
intermediate incidence of IGVH somatic 
hypermutation, and therapy demanding disease. 
These features with the clinical outcome place a 6q 
deletion CLL in an intermediate-risk group (Cuneo 
et al 2004). Lately, it was observed that deletion in 
6q16 appears to be the most frequent region in CLL 
and could be associated with a more widespread 
disease when present as the sole abnormality 
(Dalsass et al 2013). 
Prognosis 





The frequency of 6q deletions in NHL ranges from 
15-30% of cases by karyotype, mostly accompanied 
by other chromosomal abnormalities in particular 
t(14;18).  In a large series of lymphoma cases, Offit 
et al found 6q deletions in 20% of cases. They 
identified three regions of minimal deletions that 
may be associated with specific subtypes of 
lymphomas and different clinical behavior; 6q24-
q27 deletion in intermediate-grade NHL; and 6q23 
deletion noted in low-grade lymphoma lacking 
t(14;18). Taborelli et al characterized 6q deletions in 
35 malignant HL and NHL lymphomas, using 
conventional cytogenetics and FISH probes 
targeting 7 molecular regions along 6q.  
Conventional cytogenetics revealed a 6q deletion in 
46% of lymphomas while interphase FISH 
demonstrated deletions in 94%; the deletions were 
discontinuous, involving nonadjacent molecular 
regions. They concluded although 6q deletion is a 
common lesion in all types of lymphomas, specific 
deletion patterns seem to characterize different 
histological types, suggesting that different tumor 
suppressor genes play different roles in different 
types of lymphomas. Two specific 6q regions 
deleted in diffuse large B cell lymphomas but not in 
follicular lymphomas that may be implicated in the 
disease transformation.  On this basis of these 
observations, 6q deletion appears to be a dynamic 
mutation involving different molecular regions 
during progression of the disease (Taborelli et al 
2006).  
In Hodgkin lymphoma, the incidence of 6q deletion 
is not well determined due to scarcity and low 
mitotic index of the Hodgkin and Reed Sternberg (H-
RS) cells in culture. Using molecular approach, Re 
et al detected allelic losses and imbalances on 
chromosome 6q in most HL cases (78%). The 
detailed mapping using additional microsatellite 
markers on 6q led to delineation of a 3.3-Mb region 
on 6q25. They concluded that  allelotyping of single 
H-RS cells revealed monoallelic chromosomal 
deletions and genomic imbalances on 6q that might 
affect genes critically involved in the pathogenesis 
of H-RS cells (Re et al 2003). 
Clinics 
Cytogenetic analyses indicate that different regions 
of loss define distinct clinical-pathological subsets of 
lymphoma. 
Prognosis 
Deletion of 6q21 is most frequently associated with 
a high-grade lymphoma and correlates with poor 
prognosis. 
Disease 
Waldenström Macroglobulinemia (WM) 
Note 
Lymphoplasmacytic lymphoma (LPL) is the 
pathological designation of WM as proposed by 
WHO Classification of Tumors. Cytogenetic studies 
on WM are limited due to rarity of the disease and 
low mitotic index of the tumor cells. Deletion of 6q 
is the most frequent recurrent aberration reported in 
6-16% of WM cases by karyotype. However, FISH 
using probes targeting different chromosomal 
segments on 6q, Schop et al identified deletions of 
6q in over 50% of WM cases. The minimal deletion 
region (MDR) was between 6q23 and 6q24.3 and the 
SHPRH gene locus at 6q24, was most frequently 
deleted (Schop et al 2006). High resolution array-
CGH identified two non-overlapped regions in about 
95% of WM cases covering 1.4 Mb and 3.4 Mb on 
6q21-q22.1 (MDR1) and 6q23 (MDR2), 
respectively. Potential target genes localized inside 
those regions are PRDM1 (MDR1) and TNFAIP3 
(MDR2), two tumor suppressor genes that have been 
associated with the pathogenesis of other B-cell 
neoplasia (Braggio et al, 2009). 
Clinics 
WM patients with deletion of 6q are more likely to 
display features of adverse prognosis, such as higher 
levels of beta2-microglobulin and monoclonal 
paraprotein and a greater tendency to display anemia 
and hypoalbuminemia. The incidence of 6q deletions 
is also higher among WM patients with advanced 
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disease but not in the premalignant phase of the 
disease (Ocio et al, 2006). 
Prognosis 
The cohort study from Spain (Ocio et al 2006) 
presented that  WM patients with 6q deletions 
required earlier treatment, however, recent study 
(Chang etal 2009) found no significant difference in 
the requirement for treatment between 6q deleted 
and non-deleted groups, and the time to the treatment 
was also similar between these two groups. 
However, both studies demonstrated no significant 
difference in overall survival between WM patients 
with and without 6q deletions. 
Disease 
Natural Killer cell Lymphoma/Leukemia (NKLL) 
Note 
NK is a rare group of highly aggressive 
hematolymphoid malignancies characterized by 
neoplastic proliferation of NK-cells. Deletions of 6q 
have been identified in almost 50% of cases with a 
common region deletion at 6q21-q25. Molecular 
study on 25 NKLL cases identified LOH of 6q in 
50% of NK leukemia and in 100% of NK lymphoma 
with 6q21 region being lost in most cases (Ohshima 
et al, 2002). PRDM1 and FOXO3 at 6q21 are 
considered to play an important role in the 
pathogenesis of NK-cell neoplasms. 
Disease 
Plasma Cell Myeloma (PCM) 
Note 
Deletions of 6q in PCM have been identified in 
approximately 1/3 of cases with abnormal 
karyotype; not seen as a sole abnormality. However; 
its clinical significance has been addressed yet 




Deletion of 6q is an infrequent abnormality seen 
mostly in conjunction with a complex karyotype. 
However, as a sole abnormality it is very rare, 
described in isolated cases of MDS and AML (Hirata 
et al 1992; Gozzetti et al, 2009). The clinical 
significance of deletion 6q is not clear, due to small 
number of patients. The molecular mechanism by 
which this deletion causing MDS or AML is not 
addressed, but the most probable mechanism is loss 
of a tumor suppressor gene located on chromosome 
arm 6q. 
Genes involved and 
proteins 
Note 
The variable size and the complexity the deleted 
segments of 6q suggest the presence of multiple and 
potentially cooperating tumor suppressor genes. 
Thelander et al outlined the deletion patterns of 6q 
using a chromosome 6 specific tile path array in four 
different types of hematological malignances. The 
PRDM1, FOXO3A, and HACE1 genes at 6q21 and 
TNFAIP3 gene at 6q23.3 - 24.1 are considered 
candidate tumor suppressor genes that have been 
reported to be inactivated in B-cell malignancies 
(Thelander et al 2006). Other candidate genes 
proposed in T- cell neoplasms are EPHA7, 
CASP8AP2, and GRIK2 at 6q15-q16. 
PRDM1 (PR domain containing 1, 




PRDM1 (PR Domain-Containing Protein 1); 
alternative symbols; BLIMP1 (B Lymphocyte-
Induced Maturation Protein 1); PRDIBF1 (Positive 
Regulatory Domain I-Binding Factor 1) 
Protein 
PRDM1 encodes BLIMP1 which is a zinc finger 
protein expressed upon plasmacytic differentiation 
but it is also expressed in T cells, granulocytes, 
macrophages, epithelial cells, and germ cells.  
BLIMP1 protein acts as a repressor of beta-
interferon (IFNB1) gene expression. One major role 
for BLIMP1 inactivation is to block terminal 
differentiation of B cells by suppressing the 
expression of genes implicated in B cell receptor 
signals and cell cycle progression such as BCL6 and 
PAX5. This concept is supported by the observation 
that introduction of BLIMP1 into a diffuse large B 
cell lymphoma (DLBCL) cell line leads to G1 cell 
cycle arrest. Functional studies provided evidences 
that BLIMP1 is a tumor suppressor gene whose 
inactivation may contribute to lymphomagenesis by 
blocking post-GC differentiation of B cells toward 
plasma cells (Kwon et al, 2009; Mandelbaum et al, 
2010). 
Somatic mutations 
Somatic mutations that induce inactivation of 
PRDM1 gene occur through a variety of genetic 
means including  homozygous deletions, truncating 
or missense mutations, and transcriptional repression 




Most of these cases with inactive mutations are 
accompanied by heterogeneous 6q deletions or DNA 
methylation, indicating that biallelic inactivation 
occurs frequently. 
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FOXO3A (Forkhead Box O3A); alternative symbol; 
FKHRL1(Forkhead in Rhabdomyosarcoma-Llike 
1); It has at least 3 exons and 2 introns, including an 
intron located within the coding sequence of the 
forkhead domain that spans at least 90 kb. 
Protein 
FOXO3A gene belongs to the forkhead family of 
transcription factors which are characterized by a 
distinct forkhead domain that is highly conserved 
among various biologic species. A variant of 
FOXO3A gene is associated with longevity in 
human.  FOXO3A functions as a trigger for 
apoptosis through regulation of a large subset of 
genes involved in DNA repair, cell cycle regulation, 
and apoptosis. Translocation of this gene with the 
MLL (KMT2A) was found in a case of secondary 
AML with t(6;11)(q21;q23) . FOXO3 expression 
was down-regulated in most NK-cell neoplasms and 
re-expression of FOXO3 suppressed proliferation of 
the NK cell line. It was shown that the inhibition of 
cell growth by FOXO3 is due to the induction of 
apoptosis and cell-cycle arrest. These findings 
indicate that FOXO3 plays a role as a tumor-
suppressor gene in NK-cell neoplasms (Karube et al 
2011). 
Somatic mutations 
Genomic sequences of protein-coding regions and 
splice junction were analyzed on 33 clinical samples 
of NK neoplasms (Karube et al, 2011). Somatic 
missense mutations were found in 3 clinical samples 
but, no mutations were detected in the splice 
junctions. 
TNFAIP3 (tumor necrosis factor, 




TNFAIP3 (Tumor Necrosis Factor Alpha Induced 
Protein 3); alternative symbol; A20. 
Protein 
TNFAIP3 encoding A20 is a cytoplasmic zinc finger 
protein that acts as a negative regulator of the nuclear 
factor kappa-B (NFKB) activity and tumor necrosis 
factor (TNF)-mediated programmed cell death. 
TNFAIP3 polymorphisms have been associated with 
autoimmune diseases, such as rheumatoid arthritis 
and systemic lupus erythematosus. Schmitz et al 
demonstrated TNFAIP3 as a novel tumor suppressor 
gene by showing frequent somatic and clonal 
biallelic inactivation of this gene in HL and B-cell 
lymphoma. They presented evidence that loss of A20 
function contributes to the constitutive activity of the 
transcription factor NFKB and the survival and/or 
proliferation of the cells (Schmitz et al 2009). 
Somatic mutations 
TNFAIP3 (A20) is inactivated by somatic mutations 
such as base pair deletions, duplication and a single 
base pair insertion all leading to truncated 
polypeptides lacking the functionally relevant 
domains. TNFAIP3 somatic mutations were reported 
in 44% of cHL, 36% of primary mediastinal B-cell 
lymphoma and 25% of marginal zone lymphoma 
(Honma et al, 2009). In most mutated cases, both 
TNFAIP3 alleles were inactivated, including 
frequent chromosomal deletions of TNFAIP3/6q23.  
Biallelic deletions of TNFAIP3 have also been 
identified in DLBCL and ocular adnexal marginal B-
cell lymphomas. Recently, monoallelic deletions of 
TNFAIP3 were identified in 38% of WM patients 
and in those cases the TNFAIP3 transcript 
expression levels were significantly lower than in the 
group of patients with two copies of the gene. This 
suggests that haploinsufficiency of TNFAIP3 can 
predispose to the development of WM (Braggio et 
al, 2009). 
HACE1 (HECT domain and ankyrin 
repeat containing E3 ubiquitin 




HECT1 (Domain and Ankyrin Repeat Containing E3 
Ubiquitin Protein Ligase 1); alternative symbols; 
RPD3L1; KIAA1320 
Protein 
HACE1 gene encoding a protein  belongs to the 
HECT family of ubiquitin ligases (HECT E3), which 
have intrinsic catalytic activity and specificity for 
substrates involved in the regulation of growth and 
apoptosis. HACE1 inhibits the tumor suppressor 
gene RARB, ubiquitylates RAC1, which is a rho-
GTPase involved in cell proliferation and G2/M 
cycle progression and degrades cyclin D1 through 
the control of ROS1. HACE1 is down-regulated in 
Wilms tumors and gastrointestinal carcinomas, 
mediated through hypermethylation of the HACE1 
promoter.  In colorectal carcinomas 
hypermethylation of HACE1 is associated with the 
severity of clinicopathological findings, especially 
lymph node metastasis. The HACE1 was 
demonstrated to be a tumor suppressor gene in NK 
cell malignancies and to be down-regulated through 
a deletion and DNA hypermethylation, and its 
alteration may play a crucial role in NK cell 
lymphomagenesis (Karube et al blood 2011). 
Recently Bouzelfen et al reported HACE1 as a 
candidate tumor suppressor gene in B-cells 
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lymphomas down-regulated by deletion and  
epigenetic mechanisms; deletions were observed in 
40% of cases whereas hypermethylation of the 
HACE1 promoter CpG177 island was found in 60% 
of cases and in all tested B-cell lymphoma lines. 
They concluded that HACE1 can act as a 
haploinsufficient tumor suppressor gene in most B-
cell lymphomas and can be downregulated by 
deacetylation of its promoter region chromatin, 
which makes HACE1 a potential target for HDAC 
inhibitors (Bouzelfen et al, 2016). 
Somatic mutations 
Mutations in HACE1 have not been found in the 
coding or promoter regions of any cancer studied to 
date. 




EPHA7 (Ephrin type-A receptor 7), alternative 
symbol; HEK11. 
Protein 
EPHA7 gene encoding 998 amino acids protein 
belongs to the ephrin receptor subfamily of the 
protein-tyrosine kinase family. EPH and EPH-
related receptors have been implicated in mediating 
developmental events, particularly in the nervous 
system. Previous studies showed that the role of this 
gene in cancer development may be controversial. 
Although EPHA7 is upregulated in acute leukemia 
and in a variety of solid tumors, evidences of Epha7 
downregulation have been reported in B-cell 
lymphoma, T-cell leukemia, and colon cancer. In 
lymphoma, Epha7 downregulation occur by 
promoter hypermethylation or loss of heterozygosity 
or a combination of both mechanisms. The pattern of 
DNA hypermethylation is similar in various 
lymphomas as well as in colorectal cancer, 
suggesting that a common methylation profile is 
shared by different type of tumors (Lopez-Nieva et 
al 2012). The study by Oricchio et al on follicular 
lymphoma demonstrated that the the expression of 
EPHA7 gene is completely lost in over 70% of cases. 
The loss of expression was affected by differential 
promoter methylation caused by extensive CpG 
island methylation or hemizygous 6q deletions. They 
concluded that EPHA7 acts as a tumor suppressor in 
follicular lymphoma and is a promising candidate for 
translational development. Specifically, they fused 
EPHA7 to the anti-CD20 antibody, to allow 
delivering EPHA7's tumor suppressive activity 
directly to the CD20 expressing lymphoma cells 
(Oricchio et al 2010 et al). 
Somatic mutations 
Oricchio et al study did not detect EPHA7 mutations 
in the 24 FL cases. 





CASP8AP2 (Caspase 8 Associated Protein 2); 
alternative symbols FLASH, RIP25. 
Protein 
CASP8AP2 gene encodes a protein highly similar to 
the mouse apoptotic protein FLASH.  In human 
Casp8AP2 associates with CASP8 (caspase 8) to 
form the death-inducing signaling complex (DISC) 
which regulates the programmed cell death and cell 
cycle survival.  
The clinical significance of CASP8AP2 expression 
was studied in pediatric ALL; patients with low 
CASP8AP2 expression at diagnosis displayed high 
minimum residual disease (MRD), high relapse 
rates, lower relapse-free survival and inferior overall 
survival, in comparison to the higher-expression 
group (Jiao et al 2012).  
On the other hand high expression of this gene is 
associated with a greater tendency of leukemic cells 
to undergo apoptosis.  
Flotho et al considered the CASP8AP2 expression is 
an independent prognostic marker for relapse in 
ALL (Flotho C et al., 2006).  
Furthermore, Remke et al identified a deletion of 
6q15-16.1 in 12% of T-ALL patients.  
The deletion included the CASP8AP2 gene whose 
expression was the single most down-regulated 
among other genes in that region.  
The down regulation of CASP8AP2 has been 
associated with poor early treatment response 
(Remke et al 2012).  
The deletion of CASP8AP2 appears to interfere with 
the apoptotic pathways that are targeted by 
chemotherapy used in the induction phase of the 
ALL protocol. 
Somatic mutations 
While frame shift mutations of this gene have been 
describe in solid tumors, no mutations were found in 
DLBCL, pointing to a potential haploinsufficiency 
effect of this gene in lymphoma. 
GRIK2 (glutamate ionotropic receptor 




GRIK2 (Glutamate Ionotropic Receptor Kainate 
Type Subunit 2); alternative symbols GluK2, MRT6. 
DNA/RNA 
GRIK2 gene comprises 16 exons 
Protein 
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GRIK2 gene encodes a subunit of a kainate 
glutamate receptor. Glutamate receptors mediate the 
majority of excitatory neurotransmission at many 
synapses in the central nervous system. Sinclair et al 
used FISH to identify a candidate tumor suppressor 
gene in ALL with 6q deletion. They identified a 4.8-
Mb region of minimal deletion and singled out 
GRIK2 as the gene most frequently affected by 
deletions of 6q in ALL. This gene was additionally 
analyzed for inactivating mutations in cases of ALL 
carrying heterozygous chromosome 6q deletions and 
for levels of expression in a range of normal and 
malignant hematopoietic cells. Expression of GRIK2 
was low in normal hematopoietic cells compared 
with levels in brain but was most prominent in those 
of T- lineage, and it was consistently detected among 
T-cell leukemias, except in the presence of 6q 
deletion.  
These observations support the possibility that in at 
least T-ALL, haploinsufficiency might reduce 
GRIK2 expression below a critical tumor protective 
threshold level (Sinclair et al, 2004). 
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